|
|
|
|
|
|
|
 |
 |
||
|
Gordon Amidon, Ph.D. - President
Gordon received his B.S. degree from the State University of New York, Buffalo (1967), his M.A. degree in mathematics (1970), and his Ph.D. in pharmaceutical chemistry (1971) from the University of Michigan. From 1971 to 1981 he was a member of the faculty at the University of Wisconsin. In 1981 he became director of Pharmaceutical Research at Merck/INTERx, in Lawrence, Kansas. He was appointed Professor of Pharmaceutics at the University of Michigan in 1983 and was named the Charles R. Walgreen, Jr., Professor of Pharmacy in 1994. Gordon has published extensively in journals, with over 170 published papers and 250 abstracts. He has contributed chapters to over 30 books and monographs. He is co-editor of three books, The Chemical Stability of Pharmaceutics, Peptide-based Drug Design: Controlling Transport, and Metabolism and Pharmacokinetic Analysis, A Practical Approach. Gordon received the Ebert Prize of APhA in 1974 and 1981, and was co-recipient in 1984. In 1996 he received the Scheele Award of Swedish Academy of Pharmaceutical Sciences for outstanding contributions to the field of oral drug delivery and biopharmaceutics. He is a fellow of AAPS (and served as president in 1998), APhA/APS, and AAAS. He is also a member of the Controlled Release Society (and served as president in 1994), AACP, ACS, and the American Peptide Society. Shinji Yamashita, Ph.D. – Vice President
His research interests include drug absorption, drug metabolism, drug delivery systems and PK/PD. Especially, he has been focusing on the screening of intestinal drug absorption by in vitro method using Caco-2 cultured cells and by in silico computational approach. In 2002, he started to organize "Focus Group of Drug Absorption" with 25 pharmaceutical companies in Japan. He has published over 60 original research articles and book chapters. John R. Crison, Ph.D. - Treasurer
Prior to Pfizer, John started at TSRL Inc, in Ann Arbor, MI as a Research Scientist in 1993 and was Vice President upon his departure. Prior to graduate school, he was a Research Pharmacist at the Upjohn Company and was involved in a variety of research projects including polymer synthesis, emulsions, aqueous and oil suspensions for oral and intramuscular delivery, sustained release implantable devices, peptide delivery and microencapsulation. He also has experience with particle size reduction, tableting, sterile manufacturing of injectables, spray drying, fluid bed granulation, freeze drying and GMP manufacturing. During his graduate career, John studied the dissolution of water-insoluble drugs into aqueous, micellar and emulsion systems, and correlated these results with their in vivo absorption. He has continued this fundamental interest by contributing to the proposed Biopharmaceutics Drug Classification scheme and in developing methods for establishing in vitro/in vivo correlations (IVIVC) for setting biopharmaceutical drug standards. His current interests include formulation and controlled release approaches to drug delivery, the effect of intestinal transit time on the variability of drug absorptions, the effect of particle size and size distribution on the absorption of water insoluble drugs, methods for correlating in vivo drug absorption with in vitro dissolution and gene therapy. John received his B.S. degree in pharmacy in 1977, his M.S. degree in pharmaceutics in 1990, and his Ph.D. degree in pharmaceutics in 1992 from the University of Michigan. He is a member of AAPS, APhA, and CRS. He is also an Adjunct Assistant Professor of Pharmaceutics at the University of Michigan. John M. Hilfinger, Ph.D. – Secretary
John received his B.S. degree in chemistry from the State University of New York at Syracuse in 1977, and his Ph.D. in biochemistry at the University of Michigan Medical School in 1984. During his postdoctoral work at the University of Michigan, John acquired extensive expertise in molecular biology, protein chemistry, tissue culture techniques, and virology. He has worked on gene regulation in widely diverse biological systems, from ribonucleotide reductase regulation in bacteriophage T4 to HIV-2 and adenoviral expression in human cultured cells. Several papers, review articles, and book chapters have resulted from this work. John is a member of AAPS, CRS, and AAAS. Directors Maria del Val Bermejo Sanz, Ph.D. Jack Cook, Ph.D. Peter Langguth, Ph.D. Kyung-dall Lee, Ph.D. Hans Lennernas, Ph.D. Mitsuru Hashida James Polli, Ph.D. Ikumi Tamai, Ph.D. Lawrence Yu, Ph.D. |
|
|
| About DDF | Events | Board of Directors | Contact | Home | |||
| Copyright© 2005 Drug Delivery Foundation. All rights reserved. |
Gordon is internationally recognized for his research in the field of solubility, transport phenomena, prodrugs, and drug absorption. He is actively involved in developing the Biopharmaceutics Classification System (BCS) with the FDA, which will serve as a basis for international drug regulation. 
Dr. Shinji Yamashita is a Professor of Faculty of Pharmaceutical Sciences at Setsunan University, Japan. After receiving Master degree of Pharmaceutical Science in 1982 at Kyoto University, he started his carrier as an academic scientist in Jyosai University as Associate Researcher of Pharmaceutical Sciences. In 1985, he moved to Setsunan University and was promoted to Assistant Professor (1989), Associate Professor (1995) and full Professor (2001). He received his Ph.D. degree in 1987 from the Kyoto University supervised by Prof. Hitoshi Sezaki. From 1992 until 1993 he did post-doctoral research work in college of pharmacy, the University of Michigan under Prof. Gordon L. Amidon.
John is currently the Principle Scientist and Head of Technology Assessment and Product Enhancement for Pharm R & D at Pfizer.
John is the Executive Vice President of TSRL Inc. He joined the organization in 1994 and has been responsible for implementing and managing a strong, extramurally-funded research and development program directed at drug formulations, drug delivery, prodrugs, and gene delivery. His work includes development of freeze-dried recombinant adenovirus as a potential oral dosage form, microencapsulated oral vaccine formulations, controlled release formulation of recombinant adenoviral vectors, and development of improved drug permeability screens for prodrugs and transporters.